Research News from the School

With over 70 drop-in and bookable events, Open Cambridge encourages people to discover more about their local history and communities. Taking place over 10 days, here is a preview of some of the events taking place. 

Experience two iconic Cambridge sites this September by booking on to guided tours of the Mullard Radio Astronomy Observatory (MRAO) and the University of Cambridge’s Senate House. At MRAO, discover more about mysterious dishes which are dotted over the Cambridgeshire countryside. You’ll get up close to the One-Mile Telescope, 5-km Ryle Telescope, and the Arcminute Microkelvin Imager as well as see inside some of the control rooms and learn about the unique history of the site and some of the important discoveries made here. In the tours of Senate House, led by the University’s Ceremonial Officer, find out what goes on in this Grade 1 listed building during graduations as well as some of the incredible history the building as played host to.  

Learn about the experiences of over 2000 Cambridgeshire soldiers who were sent last minute by Churchill to the failed defence of Singapore in WWII in a special talk by Lewis Herbert, former Leader of Cambridge City Council. On the 80th anniversary of the release from Japanese Army slavery of our Far East Prisoners of War (FEPOWs) in September 1945, this talk will pay tribute to them and their families, particularly over 800 locally who never made in home - over 4 in every 10. 

This year marks 250 years since the birth of Jane Austen and to celebrate King’s College Library and Archives are hosting an exhibition showcasing first and early editions of the author’s much-loved novels, alongside the autograph manuscript of her unfinished novel Sanditon and treasures highlighting the Austen family’s connection with the College. This one-day event is a rare opportunity to look inside the College’s beautiful early nineteenth-century library designed by the architect William Wilkins. 

Back in May, The Sainsbury Laboratory here in Cambridge were part of a team winning a silver-gilt medal at the RHS Chelsea Flower Show. For Open Cambridge, enjoy a behind-the-scenes tour of the lab, see some of the award-winning display and have a go at some of the interactive activities the team took to Chelsea. 

Try your hand at the world’s fastest growing sport, Padel, in a free 55-minute taster session at the Cambridge University Sports Centre. A fun, sociable mix of tennis and squash, each session is led by a qualified coach and great for beginners, so you’ll learn the rules, try out some shots, and experience what makes padel so popular. 

Cambridge Samaritans will be joining Open Cambridge for the first time this year. For over 60 years, they have been there—day or night—for anyone struggling to cope or in distress, offering a safe space to talk without judgement or pressure. Join a special online event to find out more about the work the charity is doing on the helplines and in the local community and discover Samaritans’ unique approach to supporting those in emotional distress and our work in reducing the number of suicides. 

Also, in the programme for the first time, are two tours of the Biomedical Campus. The first, delivered by Sociologists and residents David Skinner and Will Brown, considers the past, present, and future of the Campus from the perspective of the people who live around it. 

The second tour will explore landmark institutions like Addenbrooke’s and Royal Papworth Hospitals, the Laboratory of Molecular Biology, and AstraZeneca’s global HQ as well as give visitors the opportunity to learn about the upcoming Cancer and Children’s Hospitals, world-first surgeries, and the collaborative spirit that drives breakthroughs from bench to bedside. 

Zoe Smith, Open Cambridge Manager, said: “Each year we’re blessed with such an incredible and unique programme of events. From garden and walking tours, to learning more about some of the amazing work our local community organisations undertake, this year’s programme opening doors to the residents of Cambridge”. 

Jo McPhee, Civic Engagement Manager at the University of Cambridge said: “Open Cambridge is a great way for our University and local communities to come together and celebrate our shared history and incredible stories behind our spaces, places and people. This year’s programme is full of exciting events that bring those stories to life, showcasing the the depth and diversity of our collective heritage.” 

The full Open Cambridge programme can be viewed here: https://www.opencambridge.cam.ac.uk/events. Open Cambridge is part of the national Heritage Open Days. It is designed to offer special access to places that are normally closed to the public or charge admission. The initiative provides an annual opportunity for people to discover the local history and heritage of their community. It is run by the Public Engagement team at the University of Cambridge who also deliver the Cambridge Festival, which takes place each Spring. 

Bookings are now open for Open Cambridge 2025 (12-21 September). This September the public can enjoy tours of College gardens, exhibitions from hidden archives, tours of University sites not usually open to the public as well as open sites across the city, all free of charge.

A group of people walk up to a radio telescope

The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.

Yes

With over 70 drop-in and bookable events, Open Cambridge encourages people to discover more about their local history and communities. Taking place over 10 days, here is a preview of some of the events taking place. 

Experience two iconic Cambridge sites this September by booking on to guided tours of the Mullard Radio Astronomy Observatory (MRAO) and the University of Cambridge’s Senate House. At MRAO, discover more about mysterious dishes which are dotted over the Cambridgeshire countryside. You’ll get up close to the One-Mile Telescope, 5-km Ryle Telescope, and the Arcminute Microkelvin Imager as well as see inside some of the control rooms and learn about the unique history of the site and some of the important discoveries made here. In the tours of Senate House, led by the University’s Ceremonial Officer, find out what goes on in this Grade 1 listed building during graduations as well as some of the incredible history the building as played host to.  

Learn about the experiences of over 2000 Cambridgeshire soldiers who were sent last minute by Churchill to the failed defence of Singapore in WWII in a special talk by Lewis Herbert, former Leader of Cambridge City Council. On the 80th anniversary of the release from Japanese Army slavery of our Far East Prisoners of War (FEPOWs) in September 1945, this talk will pay tribute to them and their families, particularly over 800 locally who never made in home - over 4 in every 10. 

This year marks 250 years since the birth of Jane Austen and to celebrate King’s College Library and Archives are hosting an exhibition showcasing first and early editions of the author’s much-loved novels, alongside the autograph manuscript of her unfinished novel Sanditon and treasures highlighting the Austen family’s connection with the College. This one-day event is a rare opportunity to look inside the College’s beautiful early nineteenth-century library designed by the architect William Wilkins. 

Back in May, The Sainsbury Laboratory here in Cambridge were part of a team winning a silver-gilt medal at the RHS Chelsea Flower Show. For Open Cambridge, enjoy a behind-the-scenes tour of the lab, see some of the award-winning display and have a go at some of the interactive activities the team took to Chelsea. 

Try your hand at the world’s fastest growing sport, Padel, in a free 55-minute taster session at the Cambridge University Sports Centre. A fun, sociable mix of tennis and squash, each session is led by a qualified coach and great for beginners, so you’ll learn the rules, try out some shots, and experience what makes padel so popular. 

Cambridge Samaritans will be joining Open Cambridge for the first time this year. For over 60 years, they have been there—day or night—for anyone struggling to cope or in distress, offering a safe space to talk without judgement or pressure. Join a special online event to find out more about the work the charity is doing on the helplines and in the local community and discover Samaritans’ unique approach to supporting those in emotional distress and our work in reducing the number of suicides. 

Also, in the programme for the first time, are two tours of the Biomedical Campus. The first, delivered by Sociologists and residents David Skinner and Will Brown, considers the past, present, and future of the Campus from the perspective of the people who live around it. 

The second tour will explore landmark institutions like Addenbrooke’s and Royal Papworth Hospitals, the Laboratory of Molecular Biology, and AstraZeneca’s global HQ as well as give visitors the opportunity to learn about the upcoming Cancer and Children’s Hospitals, world-first surgeries, and the collaborative spirit that drives breakthroughs from bench to bedside. 

Zoe Smith, Open Cambridge Manager, said: “Each year we’re blessed with such an incredible and unique programme of events. From garden and walking tours, to learning more about some of the amazing work our local community organisations undertake, this year’s programme opening doors to the residents of Cambridge”. 

Jo McPhee, Civic Engagement Manager at the University of Cambridge said: “Open Cambridge is a great way for our University and local communities to come together and celebrate our shared history and incredible stories behind our spaces, places and people. This year’s programme is full of exciting events that bring those stories to life, showcasing the the depth and diversity of our collective heritage.” 

The full Open Cambridge programme can be viewed here: https://www.opencambridge.cam.ac.uk/events. Open Cambridge is part of the national Heritage Open Days. It is designed to offer special access to places that are normally closed to the public or charge admission. The initiative provides an annual opportunity for people to discover the local history and heritage of their community. It is run by the Public Engagement team at the University of Cambridge who also deliver the Cambridge Festival, which takes place each Spring. 

Bookings are now open for Open Cambridge 2025 (12-21 September). This September the public can enjoy tours of College gardens, exhibitions from hidden archives, tours of University sites not usually open to the public as well as open sites across the city, all free of charge.

A group of people walk up to a radio telescope

The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.

Yes

Researchers have conducted the world’s biggest ever bird survey, recording 971 different species living in forests and cattle pastures across the South American country of Colombia. This represents almost 10% of the world’s birds.

They combined the results, gathered over a decade, with information on each species’ sensitivity to habitat conversion to find that the biodiversity loss caused by clearing rainforest for cattle pasture is on average 60% worse than previously thought.

Until now, understanding the biodiversity impact of land-use change has generally involved small-scale, local surveys. The researchers say that this approach does not represent the larger-scale damage caused to nature.

When forests are converted to pasture, some species win and others lose. Measuring the biodiversity loss at local scale does not capture the larger-scale effect of forest conversion, which is occurring across the ranges of many different species. While the same species usually survive on pastureland, a wide range of other species don’t, so overall biodiversity is more severely reduced at large scale.

The results are published today in the journal Nature Ecology and Evolution.

Professor David Edwards in the University of Cambridge’s Department of Plant Sciences and Conservation Research Institute, senior author of the report, said: “This is a really surprising result. We found that the biodiversity loss caused by clearing rainforest for pastureland is being massively underestimated.”

He added: “When people want to understand the wider impact of deforestation on biodiversity, they tend to do a local survey and extrapolate the results. But the problem is that tree clearance is occurring at massive spatial scales, across all sorts of different habitats and elevations.

“When we looked the biodiversity impact of deforestation across thirteen different eco-regions in Colombia, we found a 62% greater biodiversity loss than local survey results would indicate.”

The study also showed that at least six different eco-regions – that is, regions containing distinct types of plants and animals - must be considered for an accurate assessment of overall biodiversity impact. This is because the species in different eco-regions have different sensitivities to habitat conversion.

Biodiversity offsetting schemes, which aim to compensate for species losses caused by developments in one place by boosting biodiversity in another, rely on accurate measures of biodiversity.

Trees are also being cleared at huge scales in Colombia and other tropical regions to create growing space for major agricultural crops including rubber, oil palm, sugar cane and coffee.

Edwards said: “The food we eat comes with a much great environmental cost than we thought. We need policy makers to think much more about the larger scale biodiversity impact of deforestation.”

Tropical birdsong recordings

The team studied Columbia’s birdlife across its diverse landscapes for over seven years, recording the song of hundreds of bird species to help them identify the species present in landscapes across the country, from pasture to mountain forest. In about 80% of cases the birds were heard but not seen, requiring the team to make identifications from the sounds alone.

With information about the birds, including their size and diet, the team could predict which other species were likely to be living in the same regions and how they too would respond to deforestation.

A highly biodiverse country

Colombia is home to some of the most beautiful and exotic animal and plant life in the world, with almost one third made up of rainforest.

Particularly biodiverse areas, including the Caqueta moist forests and the Napo moist forests, can have 500-600 different bird species within an area of ten square kilometres – but many of these species have very specific habitat requirements. The study showed that if trees are cleared across their range these species are likely to die out.

Land-use change, particularly in the highly biodiverse tropics, is one of the main causes of the global biodiversity crisis.

This research was funded by the Research Council of Norway and the Natural Environment Research Council.

Reference 

Socolar, J. B. et al: ‘Tropical biodiversity loss from land-use change is severely underestimated by local-scale assessments.’ Nature Ecology and Evolution, July 2025. DOI: 10.1038/s41559-025-02779-4

In the largest ever survey of rainforest birdlife, scientists have discovered that deforestation to create pastureland in Colombia is causing around 60% more damage to biodiversity than previously estimated.

The food we eat comes with a much great environmental cost than we thought. We need policy makers to think much more about the larger scale biodiversity impact of deforestation.David EdwardsDavid EdwardsSavanna hawk is a widespread species that invades formerly forested areas after clearance

The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.

YesLicence type: Attribution-Noncommerical

Researchers have conducted the world’s biggest ever bird survey, recording 971 different species living in forests and cattle pastures across the South American country of Colombia. This represents almost 10% of the world’s birds.

They combined the results, gathered over a decade, with information on each species’ sensitivity to habitat conversion to find that the biodiversity loss caused by clearing rainforest for cattle pasture is on average 60% worse than previously thought.

Until now, understanding the biodiversity impact of land-use change has generally involved small-scale, local surveys. The researchers say that this approach does not represent the larger-scale damage caused to nature.

When forests are converted to pasture, some species win and others lose. Measuring the biodiversity loss at local scale does not capture the larger-scale effect of forest conversion, which is occurring across the ranges of many different species. While the same species usually survive on pastureland, a wide range of other species don’t, so overall biodiversity is more severely reduced at large scale.

The results are published today in the journal Nature Ecology and Evolution.

Professor David Edwards in the University of Cambridge’s Department of Plant Sciences and Conservation Research Institute, senior author of the report, said: “This is a really surprising result. We found that the biodiversity loss caused by clearing rainforest for pastureland is being massively underestimated.”

He added: “When people want to understand the wider impact of deforestation on biodiversity, they tend to do a local survey and extrapolate the results. But the problem is that tree clearance is occurring at massive spatial scales, across all sorts of different habitats and elevations.

“When we looked the biodiversity impact of deforestation across thirteen different eco-regions in Colombia, we found a 62% greater biodiversity loss than local survey results would indicate.”

The study also showed that at least six different eco-regions – that is, regions containing distinct types of plants and animals - must be considered for an accurate assessment of overall biodiversity impact. This is because the species in different eco-regions have different sensitivities to habitat conversion.

Biodiversity offsetting schemes, which aim to compensate for species losses caused by developments in one place by boosting biodiversity in another, rely on accurate measures of biodiversity.

Trees are also being cleared at huge scales in Colombia and other tropical regions to create growing space for major agricultural crops including rubber, oil palm, sugar cane and coffee.

Edwards said: “The food we eat comes with a much great environmental cost than we thought. We need policy makers to think much more about the larger scale biodiversity impact of deforestation.”

Tropical birdsong recordings

The team studied Columbia’s birdlife across its diverse landscapes for over seven years, recording the song of hundreds of bird species to help them identify the species present in landscapes across the country, from pasture to mountain forest. In about 80% of cases the birds were heard but not seen, requiring the team to make identifications from the sounds alone.

With information about the birds, including their size and diet, the team could predict which other species were likely to be living in the same regions and how they too would respond to deforestation.

A highly biodiverse country

Colombia is home to some of the most beautiful and exotic animal and plant life in the world, with almost one third made up of rainforest.

Particularly biodiverse areas, including the Caqueta moist forests and the Napo moist forests, can have 500-600 different bird species within an area of ten square kilometres – but many of these species have very specific habitat requirements. The study showed that if trees are cleared across their range these species are likely to die out.

Land-use change, particularly in the highly biodiverse tropics, is one of the main causes of the global biodiversity crisis.

This research was funded by the Research Council of Norway and the Natural Environment Research Council.

Reference 

Socolar, J. B. et al: ‘Tropical biodiversity loss from land-use change is severely underestimated by local-scale assessments.’ Nature Ecology and Evolution, July 2025. DOI: 10.1038/s41559-025-02779-4

In the largest ever survey of rainforest birdlife, scientists have discovered that deforestation to create pastureland in Colombia is causing around 60% more damage to biodiversity than previously estimated.

The food we eat comes with a much great environmental cost than we thought. We need policy makers to think much more about the larger scale biodiversity impact of deforestation.David EdwardsDavid EdwardsSavanna hawk is a widespread species that invades formerly forested areas after clearance

The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.

YesLicence type: Attribution-Noncommerical

Highlighting the last 10 years of partnership through scientific collaboration, nurturing talent and strengthening our ecosystem

Highlighting the last 10 years of partnership through scientific collaboration, nurturing talent and strengthening our ecosystem

Scientists have used an AI model to reassess the results of a completed clinical trial for an Alzheimer’s disease drug. They found the drug slowed cognitive decline by 46% in a group of patients with early stage, slow-progressing mild cognitive impairment – a condition that can progress to Alzheimer’s.

Using AI allowed the team to split trial participants into two groups: either slowly or rapidly progressing towards Alzheimer’s disease. They could then look at the effects of the drug on each group.

More precise selection of trial participants in this way could help select patients most likely to benefit from treatment, with the potential to reduce the cost of developing new medicines by streamlining clinical trials.

The AI model developed by researchers at the University of Cambridge predicts whether, and how quickly, people at early stages of cognitive decline will progress to full-blown Alzheimer’s. It gives predictions for patients that are three times more accurate than standard clinical assessments based on memory tests, MRI scans and blood tests.  

Using this patient stratification model, data from a completed clinical trial - which did not demonstrate efficacy in the total population studied - was re-analysed. The researchers found that the drug cleared a protein called beta amyloid in both patient groups as intended - but only the early stage, slow-progressing patients showed changes in symptoms. Beta amyloid is one of the first disease markers to appear in the brain in Alzheimer’s disease.

The new findings have significant implications: using AI to separate patients into different groups, such as slow versus rapidly progressing towards Alzheimer’s disease, allows scientists to better identify those who could benefit from a treatment approach - potentially accelerating the discovery of much-needed new Alzheimer’s drugs.

The results are published today in the journal Nature Communications.

Professor Zoe Kourtzi in the University of Cambridge’s Department of Psychology, senior author of the report, said: “Promising new drugs fail when given to people too late, when they have no chance of benefiting from them. With our AI model we can finally identify patients precisely, and match the right patients to the right drugs. This makes trials more precise, so they can progress faster and cost less, turbocharging the search for a desperately-need precision medicine approach for dementia treatment.”  

She added: “Our AI model gives us a score to show how quickly each patient will progress towards Alzheimer’s disease. This allowed us to precisely split the patients on the clinical trial into two groups – slow, and fast progressing, so we could look at the effects of the drug on each group.”

Health Innovation East England, the innovation arm of the NHS in the East of England, is now supporting Kourtzi to translate this AI-enabled approach into clinical care for the benefit of future patients.

Joanna Dempsey, Principal Advisor at Health Innovation East England, said: “This AI-enabled approach could have a significant impact on easing NHS pressure and costs in dementia care by enabling more personalised drug development - identifying which patients are most likely to benefit from treatment, resulting in faster access to effective medicines and targeted support for people living with dementia.”

Drugs like this are not intended as cures for Alzheimer’s disease. The aim is to reduce cognitive decline so that patients don’t get worse.

Dementia is the UK’s leading cause of death, and a major cause of mortality globally. It costs $1.3 tr per year, and the number of cases are expected to treble by 2050. There is no cure, and patients and families face high uncertainty.

Despite decades of research and development, clinical trials of treatments for dementia have been largely unsuccessful. The failure rate for new treatments is unreasonably high at over 95%, despite $43 bn having been spent on research and development. Progress has been hampered by the wide variation in symptoms, disease progression and responses to treatment among patients.

Although new dementia drugs have recently been approved for use in the US, their risk of side effects and insufficient cost effectiveness have prevented healthcare adoption in the NHS.

Understanding and accounting for the natural differences among individuals with a disease is crucial, so that treatments can be tailored to be most effective for each patient. Alzheimer’s disease is complex, and although some drugs are available to treat it they don’t work for everybody.

“AI can guide us to the patients who will benefit from dementia medicines, by treating them at the stage when the drugs will make a difference, so we can finally start fighting back against these cruel diseases. Making clinical trials faster, cheaper and better, guided by AI has strong potential to accelerate discovery of new precise treatments for individual patients, reducing side effects and costs for healthcare services,” said Kourtzi.

She added: “Like many people, I have watched hopelessly as dementia stole a loved one from me.  We’ve got to accelerate the development of dementia medicines. Over £40 billion has already been spent over thirty years of research and development - we can’t wait another thirty years.”

This research was funded by the Royal Society, Alan Turing Institute and Wellcome.

Reference 

Vaghari, D. V. et al: ‘AI-guided patient stratification improves outcomes and efficiency in the AMARANTH Alzheimer’s Disease clinical trial.’ Nature Communications, July 2025.  DOI: 10.1038/s41467-025-61355-3

Scientists have used AI to re-analyse a clinical trial for an Alzheimer’s medicine, and identified a group of patients who responded to treatment. The work demonstrates that AI can inform the design of future clinical trials to make them more effective and efficient, accelerating the search for new medicines.

With our AI model we can finally identify patients precisely, and match the right patients to the right drugsZoe KourtziMichael Hewes/ Getty

The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.

YesLicence type: Attribution-Noncommerical

Scientists have used an AI model to reassess the results of a completed clinical trial for an Alzheimer’s disease drug. They found the drug slowed cognitive decline by 46% in a group of patients with early stage, slow-progressing mild cognitive impairment – a condition that can progress to Alzheimer’s.

Using AI allowed the team to split trial participants into two groups: either slowly or rapidly progressing towards Alzheimer’s disease. They could then look at the effects of the drug on each group.

More precise selection of trial participants in this way could help select patients most likely to benefit from treatment, with the potential to reduce the cost of developing new medicines by streamlining clinical trials.

The AI model developed by researchers at the University of Cambridge predicts whether, and how quickly, people at early stages of cognitive decline will progress to full-blown Alzheimer’s. It gives predictions for patients that are three times more accurate than standard clinical assessments based on memory tests, MRI scans and blood tests.  

Using this patient stratification model, data from a completed clinical trial - which did not demonstrate efficacy in the total population studied - was re-analysed. The researchers found that the drug cleared a protein called beta amyloid in both patient groups as intended - but only the early stage, slow-progressing patients showed changes in symptoms. Beta amyloid is one of the first disease markers to appear in the brain in Alzheimer’s disease.

The new findings have significant implications: using AI to separate patients into different groups, such as slow versus rapidly progressing towards Alzheimer’s disease, allows scientists to better identify those who could benefit from a treatment approach - potentially accelerating the discovery of much-needed new Alzheimer’s drugs.

The results are published today in the journal Nature Communications.

Professor Zoe Kourtzi in the University of Cambridge’s Department of Psychology, senior author of the report, said: “Promising new drugs fail when given to people too late, when they have no chance of benefiting from them. With our AI model we can finally identify patients precisely, and match the right patients to the right drugs. This makes trials more precise, so they can progress faster and cost less, turbocharging the search for a desperately-need precision medicine approach for dementia treatment.”  

She added: “Our AI model gives us a score to show how quickly each patient will progress towards Alzheimer’s disease. This allowed us to precisely split the patients on the clinical trial into two groups – slow, and fast progressing, so we could look at the effects of the drug on each group.”

Health Innovation East England, the innovation arm of the NHS in the East of England, is now supporting Kourtzi to translate this AI-enabled approach into clinical care for the benefit of future patients.

Joanna Dempsey, Principal Advisor at Health Innovation East England, said: “This AI-enabled approach could have a significant impact on easing NHS pressure and costs in dementia care by enabling more personalised drug development - identifying which patients are most likely to benefit from treatment, resulting in faster access to effective medicines and targeted support for people living with dementia.”

Drugs like this are not intended as cures for Alzheimer’s disease. The aim is to reduce cognitive decline so that patients don’t get worse.

Dementia is the UK’s leading cause of death, and a major cause of mortality globally. It costs $1.3 tr per year, and the number of cases are expected to treble by 2050. There is no cure, and patients and families face high uncertainty.

Despite decades of research and development, clinical trials of treatments for dementia have been largely unsuccessful. The failure rate for new treatments is unreasonably high at over 95%, despite $43 bn having been spent on research and development. Progress has been hampered by the wide variation in symptoms, disease progression and responses to treatment among patients.

Although new dementia drugs have recently been approved for use in the US, their risk of side effects and insufficient cost effectiveness have prevented healthcare adoption in the NHS.

Understanding and accounting for the natural differences among individuals with a disease is crucial, so that treatments can be tailored to be most effective for each patient. Alzheimer’s disease is complex, and although some drugs are available to treat it they don’t work for everybody.

“AI can guide us to the patients who will benefit from dementia medicines, by treating them at the stage when the drugs will make a difference, so we can finally start fighting back against these cruel diseases. Making clinical trials faster, cheaper and better, guided by AI has strong potential to accelerate discovery of new precise treatments for individual patients, reducing side effects and costs for healthcare services,” said Kourtzi.

She added: “Like many people, I have watched hopelessly as dementia stole a loved one from me.  We’ve got to accelerate the development of dementia medicines. Over £40 billion has already been spent over thirty years of research and development - we can’t wait another thirty years.”

This research was funded by the Royal Society, Alan Turing Institute and Wellcome.

Reference 

Vaghari, D. V. et al: ‘AI-guided patient stratification improves outcomes and efficiency in the AMARANTH Alzheimer’s Disease clinical trial.’ Nature Communications, July 2025.  DOI: 10.1038/s41467-025-61355-3

Scientists have used AI to re-analyse a clinical trial for an Alzheimer’s medicine, and identified a group of patients who responded to treatment. The work demonstrates that AI can inform the design of future clinical trials to make them more effective and efficient, accelerating the search for new medicines.

With our AI model we can finally identify patients precisely, and match the right patients to the right drugsZoe KourtziMichael Hewes/ Getty

The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.

YesLicence type: Attribution-Noncommerical

A case study of how AstraZeneca is nurturing the talent of the future through its funded PhD programmes.

A case study of how AstraZeneca is nurturing the talent of the future through its funded PhD programmes.

New Cambridge laboratory supports the UK’s ambition of having the most advanced genomic healthcare system in the world.

New Cambridge laboratory supports the UK’s ambition of having the most advanced genomic healthcare system in the world.

Making advances in patient care through scientific collaboration and partnering on clinical trials.

Making advances in patient care through scientific collaboration and partnering on clinical trials.

A new study suggests that our ancestors’ close cohabitation with domesticated animals and large-scale migrations played a key role in the spread of infectious diseases.

The team, led by Professor Eske Willerslev at the Universities of Cambridge and Copenhagen, recovered ancient DNA from 214 known human pathogens in prehistoric humans from Eurasia.

They found that the earliest evidence of zoonotic diseases – illnesses transmitted from animals to humans, like COVID in recent times – dates back to around 6,500 years ago, with these diseases becoming more widespread approximately 5,000 years ago.

The study detected the world’s oldest genetic trace of the plague bacterium, Yersinia pestis, in a 5,500-year-old sample. The plague is estimated to have killed between one-quarter and one-half of Europe’s population during the Middle Ages.

In addition, the researchers found traces of many other diseases including:

Malaria (Plasmodium vivax) – 4,200 years ago

Leprosy (Mycobacterium leprae) – 1,400 years ago

Hepatitis B virus – 9,800 years ago

Diphtheria (Corynebacterium diphtheriae) – 11,100 years ago

This is the largest study to date on the history of infectious diseases and is published today in the journal Nature.

The researchers analysed DNA from over 1,300 prehistoric humans, some up to 37,000 years old. The ancient bones and teeth have provided a unique insight into the development of diseases caused by bacteria, viruses, and parasites.

“We’ve long suspected that the transition to farming and animal husbandry opened the door to a new era of disease – now DNA shows us that it happened at least 6,500 years ago,” said Willerslev.

He added: “These infections didn’t just cause illness – they may have contributed to population collapse, migration, and genetic adaptation.”

The significant increase in the incidence of zoonoses around 5,000 years ago coincides with a migration to north-western Europe from the Pontic Steppe – that is from parts of present-day Ukraine, south-western Russia and western Kazakhstan. The people embarking on this migration – and who to a large extent passed on the genetic profile found among people in north-western Europe today – belonged to the Yamnaya herders.

 

 

The findings could be significant for the development of vaccines and for understanding how diseases arise and mutate over time.

“If we understand what happened in the past, it can help us prepare for the future. Many of the newly emerging infectious diseases are predicted to originate from animals,” said Associate Professor Martin Sikora at the University of Copenhagen, and first author of the report.

Willerslev added: “Mutations that were successful in the past are likely to reappear. This knowledge is important for future vaccines, as it allows us to test whether current vaccines provide sufficient coverage or whether new ones need to be developed due to mutations.”

The sample material was primarily provided by museums in Europe and Asia. The samples were partly extracted from teeth, where the enamel acts as a lid that can protect the DNA against degradation as a result of the ravages of time. The rest of the DNA was primarily extracted from petrosa bones - the hardest bone in humans - located on the inside of the skull.

The research was funded by the Lundbeck Foundation.

Reference

Sikora, M et al: ‘The spatiotemporal distribution of human pathogens in ancient Eurasia.’ Nature, July 2025. DOI: 10.1038/s41586-025-09192-8

Adapted from a press release by the University of Copenhagen.

Researchers have mapped the spread of infectious diseases in humans across millennia, to reveal how human-animal interactions permanently transformed our health today.

We’ve long suspected that the transition to farming and animal husbandry opened the door to a new era of disease – now DNA shows us that it happened at least 6,500 years agoEske WillerslevMarie Louise JørkovLate Neolithic skull from Madesø.

The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.

YesLicence type: Attribution-Noncommerical

A new study suggests that our ancestors’ close cohabitation with domesticated animals and large-scale migrations played a key role in the spread of infectious diseases.

The team, led by Professor Eske Willerslev at the Universities of Cambridge and Copenhagen, recovered ancient DNA from 214 known human pathogens in prehistoric humans from Eurasia.

They found that the earliest evidence of zoonotic diseases – illnesses transmitted from animals to humans, like COVID in recent times – dates back to around 6,500 years ago, with these diseases becoming more widespread approximately 5,000 years ago.

The study detected the world’s oldest genetic trace of the plague bacterium, Yersinia pestis, in a 5,500-year-old sample. The plague is estimated to have killed between one-quarter and one-half of Europe’s population during the Middle Ages.

In addition, the researchers found traces of many other diseases including:

Malaria (Plasmodium vivax) – 4,200 years ago

Leprosy (Mycobacterium leprae) – 1,400 years ago

Hepatitis B virus – 9,800 years ago

Diphtheria (Corynebacterium diphtheriae) – 11,100 years ago

This is the largest study to date on the history of infectious diseases and is published today in the journal Nature.

The researchers analysed DNA from over 1,300 prehistoric humans, some up to 37,000 years old. The ancient bones and teeth have provided a unique insight into the development of diseases caused by bacteria, viruses, and parasites.

“We’ve long suspected that the transition to farming and animal husbandry opened the door to a new era of disease – now DNA shows us that it happened at least 6,500 years ago,” said Willerslev.

He added: “These infections didn’t just cause illness – they may have contributed to population collapse, migration, and genetic adaptation.”

The significant increase in the incidence of zoonoses around 5,000 years ago coincides with a migration to north-western Europe from the Pontic Steppe – that is from parts of present-day Ukraine, south-western Russia and western Kazakhstan. The people embarking on this migration – and who to a large extent passed on the genetic profile found among people in north-western Europe today – belonged to the Yamnaya herders.

The findings could be significant for the development of vaccines and for understanding how diseases arise and mutate over time.

“If we understand what happened in the past, it can help us prepare for the future. Many of the newly emerging infectious diseases are predicted to originate from animals,” said Associate Professor Martin Sikora at the University of Copenhagen, and first author of the report.

Willerslev added: “Mutations that were successful in the past are likely to reappear. This knowledge is important for future vaccines, as it allows us to test whether current vaccines provide sufficient coverage or whether new ones need to be developed due to mutations.”

The sample material was primarily provided by museums in Europe and Asia. The samples were partly extracted from teeth, where the enamel acts as a lid that can protect the DNA against degradation as a result of the ravages of time. The rest of the DNA was primarily extracted from petrosa bones - the hardest bone in humans - located on the inside of the skull.

The research was funded by the Lundbeck Foundation.

Reference

Sikora, M. et al: ‘The spatiotemporal distribution of human pathogens in ancient Eurasia.’ Nature, July 2025. DOI: 10.1038/s41586-025-09192-8

Adapted from a press release by the University of Copenhagen.

Researchers have mapped the spread of infectious diseases in humans across millennia, to reveal how human-animal interactions permanently transformed our health today.

We’ve long suspected that the transition to farming and animal husbandry opened the door to a new era of disease – now DNA shows us that it happened at least 6,500 years agoEske WillerslevMarie Louise JørkovLate Neolithic skull from Madesø

The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright ©University of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.

YesLicence type: Attribution-Noncommerical

Researchers from every school and more than 20 departments across the University of Cambridge gathered in February to explore the links between air quality and climate, their impacts on human health, and the challenges and opportunities for Clean Air and Net Zero.

Researchers from every school and more than 20 departments across the University of Cambridge gathered in February to explore the links between air quality and climate, their impacts on human health, and the challenges and opportunities for Clean Air and Net Zero.

Cambridge researchers are working to undo a longstanding male bias in health research, to help drive more effective healthcare for all.

Cambridge researchers are working to undo a longstanding male bias in health research, to help drive more effective healthcare for all.